Mounjaro® (tirzepatide) – the first registered dual GLP1 and GIP receptor agonist – is now available in New Zealand.
Mounjaro is a once weekly injectable medicine that acts on both GLP1 and GIP receptors to improve blood sugar control and provide clinically meaningful weight reduction in appropriate patients.
The medicine was evaluated under the Medsafe priority review pathway, which is a fast-track pathway for medicines of clinical significance that could be useful to help meet current Public Health challenges.
Mounjaro was the highest selling prescription medicine brand in Australia in 2025.
Refer to the full press release for more information.
About us:
Lilly is a medicine company making life better for people around the world. We've turned science into pioneering new discoveries for nearly 150 years, and today our medicines support more than 51 million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: treating obesity, redefining diabetes and obesity care; advancing the fight against Alzheimer's disease; providing some of the most debilitating immune system disorders; and targeting the most difficult-to-treat cancers. With each step towards a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.co.nz or follow us on LinkedIn.
Contact details:
Eliza Roel
+61 407 653 268
